Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

Insmed ($INSM) announced an update on their ongoing clinical study. Insmed Inc. has launched a Phase 1 trial called “An Open-label, Phase 1 Trial t...

Insmed’s New TPIP Liver Study Marks a Small but Important De‑Risking Step

Insmed ($INSM) announced an update on their ongoing clinical study. Insmed’s new Phase 3 trial, officially titled “A Phase 3, Randomized, Double-Bl...

Insmed Advances Phase 3 Inhaled PAH Therapy, Keeping Growth Hopes Alive

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up more than 2% on Monday (as of this writing), r...

Invesco QQQ Trust ETF (QQQ) Rebounds from Last Week’s Slump; What’s Fueling the Rise?

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.38% on Friday at the time of writing, as inv...

Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/29/26?

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.15% on Thursday morning as investors asses...

Why Is Invesco QQQ Trust ETF (QQQ) Falling Today, 5/28/26?

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.62% in Wednesday’s pre-market trading a...

Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/27/26?

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), has risen 1% over the past five trading sessions and ...

Market Cap	$35.04B	P/E Ratio	N/A
52W High	$212.75	52W Low	$90.39
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-18.0%	52W Position	6.4%
Overall Score	48	Value Score	40
Quality Score	60	Technical Score	45

EPS Current Est	$-2.54	EPS Next Est	$0.93
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$98.25	+2.55%	2.58M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INSM	$98.25	+2.6%	2.58M
3
4
5
6

INSM

INSM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Insmed Incorporated Data in Excel

Get Insmed Incorporated Data in Excel